GPT and non-alcoholic fatty liver: As expected, the ALT levels were increased in the NAFL group, whereas comorbidities such as insulin resistance (as assessed by MMT) and medication did not differ between groups, indicating a homogenous study population (Table 1, Figures S1 and S2).